NASDAQ:BMRA Biomerica (BMRA) Stock Price, News & Analysis $3.23 +0.15 (+4.87%) Closing price 04:00 PM EasternExtended Trading$3.24 +0.00 (+0.15%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biomerica Stock (NASDAQ:BMRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biomerica alerts:Sign Up Key Stats Today's Range$2.96▼$3.6650-Day Range$3.03▼$3.8852-Week Range$1.93▼$10.16Volume613,833 shsAverage Volume280,615 shsMarket Capitalization$8.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California. Read More Biomerica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks9th Percentile Overall ScoreBMRA MarketRank™: Biomerica scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Biomerica. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomerica is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomerica is -1.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomerica has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biomerica's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.31% of the float of Biomerica has been sold short.Short Interest Ratio / Days to CoverBiomerica has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biomerica has recently increased by 10.86%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomerica does not currently pay a dividend.Dividend GrowthBiomerica does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.31% of the float of Biomerica has been sold short.Short Interest Ratio / Days to CoverBiomerica has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biomerica has recently increased by 10.86%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.56 News SentimentBiomerica has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Biomerica this week, compared to 1 article on an average week.Search Interest2 people have searched for BMRA on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomerica insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.28% of the stock of Biomerica is held by institutions.Read more about Biomerica's insider trading history. Receive BMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRA Stock News HeadlinesBiomerica, Inc. Secures PLA Code for inFoods® IBS Test to Enhance Patient Access and Insurance ReimbursementJuly 2 at 8:54 AM | quiverquant.comQInFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) CodeJuly 2 at 8:08 AM | globenewswire.comBanks aren’t ready for this altcoin—are you?In crypto, timing is everything. By the time the masses catch wind of this, the biggest gains could be ancient history. Are you ready to potentially change your financial future forever?July 2 at 2:00 AM | Crypto 101 Media (Ad)Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer - MorningstarJune 27, 2025 | morningstar.comMClinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial OfficerJune 26, 2025 | finance.yahoo.comBiomerica, Inc.: Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica's Team as Chief Commercial OfficerJune 26, 2025 | finanznachrichten.deClinical Diagnostics Industry Leader Scott Madel Joins Biomerica's Team as Chief Commercial OfficerJune 26, 2025 | globenewswire.comBiomerica’s inFoods® IBS Clinical Study Results Published in June Issue of GastroenterologyJune 7, 2025 | seekingalpha.comSee More Headlines BMRA Stock Analysis - Frequently Asked Questions How have BMRA shares performed this year? Biomerica's stock was trading at $2.4008 at the beginning of the year. Since then, BMRA shares have increased by 34.5% and is now trading at $3.23. View the best growth stocks for 2025 here. How were Biomerica's earnings last quarter? Biomerica, Inc. (NASDAQ:BMRA) posted its quarterly earnings data on Monday, April, 14th. The company reported ($0.48) earnings per share (EPS) for the quarter. The firm had revenue of $1.12 million for the quarter. Biomerica had a negative net margin of 85.42% and a negative trailing twelve-month return on equity of 85.90%. When did Biomerica's stock split? Biomerica shares reverse split on the morning of Monday, April 21st 2025.The 1-8 reverse split was announced on Wednesday, April 16th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Biomerica? Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomerica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), Exxon Mobil (XOM), Avino Silver & Gold Mines (ASM) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings4/14/2025Today7/02/2025Next Earnings (Estimated)8/26/2025Fiscal Year End5/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMRA CIK73290 Webwww.biomerica.com Phone(949) 645-2111Fax949-553-1231Employees60Year Founded1971Profitability EPS (Trailing Twelve Months)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.98 million Net Margins-85.42% Pretax Margin-85.35% Return on Equity-85.90% Return on Assets-61.06% Debt Debt-to-Equity RatioN/A Current Ratio3.76 Quick Ratio2.76 Sales & Book Value Annual Sales$5.41 million Price / Sales1.52 Cash FlowN/A Price / Cash FlowN/A Book Value$3.13 per share Price / Book1.03Miscellaneous Outstanding Shares2,550,000Free Float2,164,000Market Cap$8.24 million OptionableOptionable Beta0.35 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:BMRA) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.